GB202402048D0 - Therapeutic antibodies - Google Patents
Therapeutic antibodiesInfo
- Publication number
- GB202402048D0 GB202402048D0 GBGB2402048.9A GB202402048A GB202402048D0 GB 202402048 D0 GB202402048 D0 GB 202402048D0 GB 202402048 A GB202402048 A GB 202402048A GB 202402048 D0 GB202402048 D0 GB 202402048D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- therapeutic antibodies
- antibodies
- therapeutic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biophysics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2402048.9A GB202402048D0 (en) | 2024-02-14 | 2024-02-14 | Therapeutic antibodies |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB2402048.9A GB202402048D0 (en) | 2024-02-14 | 2024-02-14 | Therapeutic antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
GB202402048D0 true GB202402048D0 (en) | 2024-03-27 |
Family
ID=90354556
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB2402048.9A Pending GB202402048D0 (en) | 2024-02-14 | 2024-02-14 | Therapeutic antibodies |
Country Status (1)
Country | Link |
---|---|
GB (1) | GB202402048D0 (en) |
Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
WO1996027011A1 (en) | 1995-03-01 | 1996-09-06 | Genentech, Inc. | A method for making heteromultimeric polypeptides |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US20040043401A1 (en) | 2002-05-28 | 2004-03-04 | Sloan Kettering Institute For Cancer Research | Chimeric T cell receotors |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2019200007A1 (en) | 2018-04-10 | 2019-10-17 | Amgen Inc. | Chimeric receptors to dll3 and methods of use thereof |
WO2021108613A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2021113679A1 (en) | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
-
2024
- 2024-02-14 GB GBGB2402048.9A patent/GB202402048D0/en active Pending
Patent Citations (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4978744A (en) | 1989-01-27 | 1990-12-18 | Arizona Board Of Regents | Synthesis of dolastatin 10 |
US5635483A (en) | 1992-12-03 | 1997-06-03 | Arizona Board Of Regents Acting On Behalf Of Arizona State University | Tumor inhibiting tetrapeptide bearing modified phenethyl amides |
US5780588A (en) | 1993-01-26 | 1998-07-14 | Arizona Board Of Regents | Elucidation and synthesis of selected pentapeptides |
WO1996027011A1 (en) | 1995-03-01 | 1996-09-06 | Genentech, Inc. | A method for making heteromultimeric polypeptides |
US6410319B1 (en) | 1998-10-20 | 2002-06-25 | City Of Hope | CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies |
US20040043401A1 (en) | 2002-05-28 | 2004-03-04 | Sloan Kettering Institute For Cancer Research | Chimeric T cell receotors |
WO2006106905A1 (en) | 2005-03-31 | 2006-10-12 | Chugai Seiyaku Kabushiki Kaisha | Process for production of polypeptide by regulation of assembly |
WO2019200007A1 (en) | 2018-04-10 | 2019-10-17 | Amgen Inc. | Chimeric receptors to dll3 and methods of use thereof |
WO2021108613A1 (en) | 2019-11-26 | 2021-06-03 | Novartis Ag | Cd19 and cd22 chimeric antigen receptors and uses thereof |
WO2021113679A1 (en) | 2019-12-06 | 2021-06-10 | Mersana Therapeutics, Inc. | Dimeric compounds as sting agonists |
Non-Patent Citations (37)
Title |
---|
"GenBank", Database accession no. BAG36664.1 |
"Uniprot", Database accession no. Q7Z7D3-1 |
A. L. SMITH ET AL., J. MED. CHEM., vol. 39, no. 11, 1996, pages 2103 - 2117 |
AGNEW, CHEM INTL. ED. ENGL, vol. 33, 1994, pages 183 - 186 |
ALLEY, CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 14, 2010, pages 1 - 9 |
ALTSCHUL ET AL., J. MOL. BIOL., vol. 215, 1990, pages 405 - 410 |
ATWELL ET AL.: "Stable heterodimers from remodeling the domain interface of a homodimer using a phage display library", J. MOL. BIOL., vol. 270, 1997, pages 26 - 35, XP002610109, DOI: 10.1006/jmbi.1997.1116 |
BRINKMANNKONTERMANN: "The making of bispecific antibodies", MABS, vol. 9, no. 2, 2017, pages 182 - 212 |
CHOI IH ET AL.: "Genomic organization and expression analysis of B7-H4, an immune inhibitory molecule of the B7 family", J IMMUNOL., vol. 171, 2003, pages 4650 - 4, XP002493422 |
CHOTHIALESK, J. MOL. BIOL., vol. 196, 1987, pages 901 - 917 |
D. BOGER, PURE & APPL. CHEM., vol. 66, no. 4, 1994, pages 837 - 844 |
DUBOWCHIKWALKER, PHARM. THERAPEUTICS, vol. 83, 1999, pages 67 - 123 |
FRENAY ET AL., INT. J. MOL. SCI., vol. 23, no. 23, 2022, pages 14918 |
GITTO ET AL., CANCER RES, vol. 83, 2023, pages 1133 |
GREENSAMBROOK ET AL.: "Molecular Cloning: A Laboratory Manual", 2012, COLD SPRING HARBOR LABORATORY PRESS |
GUNASEKARAN ET AL.: "Enhancing antibody Fc heterodimer formation through electrostatic steering effects: applications to bispecific molecules and monovalent IgG", J. BIOL. CHEM., vol. 285, 2010, pages 19637 - 19646, XP055546816, DOI: 10.1074/jbc.M110.117382 |
HA ET AL.: "Frontiers in Immunology Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications", THERAPEUTIC ANTIBODIES AND PROTEINS, vol. 7, 2016 |
I. BHATNAGARET, MAR. DRUGS, vol. 8, 2010, pages 2702 - 2720 |
J.B. RIDGWAY ET AL.: "Knobs-into-holes' engineering of antibody CH3 domains for heavy chain heterodimerisation", PROTEIN ENG., vol. 9, 1996, pages 617 - 621, XP002610995, DOI: 10.1093/protein/9.7.617 |
JOHNSON ET AL., ANTICANCER RES., vol. 15, 1995, pages 1387 - 93 |
KABAT ET AL., ANN. NY ACAD. SCI., vol. 190, 1971, pages 382 - 391 |
KABAT ET AL.: "Sequences of Proteins of Immunological Interest", 1991, NIH PUBLICATION |
LAU ET AL., BIOORG-MED-CHEM, vol. 3, 1995, pages 1305 - 12 |
LAU ET AL., BIOORG-MED-CHEM., vol. 3, 1995, pages 1299 - 1304 |
LEFRANC ET AL., DEV. COMP. IMMUNOL., vol. 29, 2005, pages 185 - 203 |
METRANGOLO ET AL., CANCERS, vol. 16, 2024, pages 447 |
MORETTI ET AL., BMC PROC, vol. 7, 2013 |
PEARSONLIPMAN, PNAS USA, 1988, pages 2444 - 2448 |
PIVOT ET AL., EUROPEAN ONCOLOGY, vol. 4, no. 2, 2008, pages 42 - 45 |
SADELAIN ET AL., CURR OPIN IMMUNOL, vol. 21, no. 2, 2009, pages 215 - 223 |
SENTER, CANCER J., vol. 14, no. 3, 2008, pages 154 - 169 |
SICA GL ET AL.: "B7-H4, a molecule of the B7 family, negatively regulates T cell immunity", IMMUNITY, vol. 18, 2003, pages 849 - 61, XP002485368, DOI: 10.1016/S1074-7613(03)00152-3 |
SMITHWATERMAN, J. MOL BIOL., vol. 147, 1981, pages 195 - 197 |
STERNER, R.C.STERNER, R.M: "CAR-T cell therapy: current limitations and potential strategies", BLOOD CANCER J., vol. 11, 2021, pages 69 |
T. L. SIMMONS ET AL., MOL. CANCER THER., vol. 4, no. 2, 2005, pages 333 - 342 |
WANG ET AL., ACTA PHARMACEUTICA SINICA B, vol. 13, no. 10, 2023, pages 4025 - 4059 |
WARD ET AL., NATURE, vol. 341, 1989, pages 544 - 546 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GB202012331D0 (en) | Therapeutic antibodies | |
GB202402048D0 (en) | Therapeutic antibodies | |
GB202402046D0 (en) | Therapeutic antibodies | |
GB202401988D0 (en) | Therapeutic antibodies | |
GB202311497D0 (en) | Therapeutic antibodies | |
GB202310818D0 (en) | Therapeutic antibodies | |
IL314314A (en) | Therapeutic antibodies | |
GB202300904D0 (en) | Therapeutic antibodies | |
GB202217993D0 (en) | Therapeutic antibodies | |
GB202209454D0 (en) | Therapeutic antibodies | |
GB202208544D0 (en) | Therapeutic antibodies | |
GB202202990D0 (en) | Therapeutic antibodies | |
GB202202635D0 (en) | Therapeutic antibodies | |
GB202413525D0 (en) | Antibodies | |
GB202411940D0 (en) | Anti-CLEC12A Antibodies | |
GB202410983D0 (en) | Antibodies | |
GB202410982D0 (en) | Antibodies | |
GB202409026D0 (en) | Antibodies | |
GB202405480D0 (en) | Antibodies | |
GB202404343D0 (en) | Antibodies | |
GB202404344D0 (en) | Antibodies | |
GB202400941D0 (en) | Antibodies | |
GB202108677D0 (en) | Therapeutic antibodies | |
GB202406710D0 (en) | Therapy | |
GB202405750D0 (en) | Therapy |